Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity

18 Nov 2020

• By Derrick Gingery

Railway tracks with switches and interchanges at a main line in Germany with geometrical structures black and white — First interchangeable exclusivity guidance is one of several the FDA is writing in the interchangeability area. • Source: Shutterstock

Related Content

Biosimilar Labeling Carve-Out Turned Erelzi's Psoriatic Arthritis, Plaque Psoriasis Uses Into 'Another Indication'

14 Mar 2018

Not A Biosimilar: Mylan’s Insulin Glargine ‘Deemed’ A BLA With Long-Awaited US FDA Approval

11 Jun 2020

Biosimilars: US FDA Asked To Clarify Thinking On Pediatric Studies, Indication Carve-Outs

22 Feb 2019

Biosimilar Insulins (Generally) Won't Need Comparative Clinical Immunogenicity Data, US FDA Says

25 Nov 2019

Mylan's Semglee Launch Marks US Multi-Source Competition To Lantus

31 Aug 2020

Biosimilar Interchangeability: Limited Exclusivity Should Mean Limited Testing – GPhA

15 Apr 2016

Related Companies

Viatris Inc.

Biocon, Ltd.

Sanofi

Sandoz Inc.

Teva Pharmaceutical Industries Ltd.

Additional Topics

United States Biosimilars Legal Issues Regulation FDA BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.